Piper Jaffray Downgrades Auspex Pharmaceuticals To Neutral

Loading...
Loading...
Analysts at Piper Jaffray downgraded
Auspex Pharmaceuticals, Inc.ASPX
from Overweight to Neutral. The price target for Auspex Pharmaceuticals has been raised from $91.00 to $101.00. Auspex Pharmaceuticals shares have gained 227.44% over the past 52 weeks, while the S&P 500 index has surged 11.42% in the same period. Auspex Pharmaceuticals' shares rose 41.53% to close at $100.36 yesterday.
Posted In: DowngradesAnalyst RatingsPiper Jaffray
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...